Internal Medicine, Hematology & Oncology · Nashville, TN
NPI
1417990367
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
250 25th Ave N, Ste 412
Nashville, TN, 37203
Phone (615) 986-7600
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.2M
43,925 services
Medicare patients, 2024
255
Average age 73
Drug cost, 2024
$7.8M
960 prescriptions
Company payments, 2025
$15K
From 38 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Ian W Flinn was code J1568 (injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg), 3,040 times for 14 patients. In total Ian W Flinn billed 43,925 services in 133 codes, and Medicare paid $1.2M.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2012-01-24.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|
| J1568 Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | Office | 3,040 | 14 | $36.28 | $110K |
| 85025 Blood Count | Office | 1,119 | 224 | $7.58 | $8,481 |
| 36415 Venipuncture Blood Collection | Office | 913 | 218 | $8.60 | $7,850 |
| 80053 Clinical Chemistry | Office | 831 | 203 | $10.34 | $8,593 |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 518 | 12 | $0.09 | $47.09 |
| 82784 Immunoassay | Office | 463 | 45 | $9.11 | $4,219 |
| M0010 Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | Office | 313 | 48 | $70.20 | $22K |
| 99214 Office E&M - Established | Office | 267 | 112 | $86.31 | $23K |
| 83615 Clinical Chemistry | Office | 261 | 53 | $5.92 | $1,545 |
| 99213 Office E&M - Established | Office | 214 | 138 | $56.39 | $12K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 208 | 135 | $11.99 | $2,495 |
| 84550 Clinical Chemistry | Office | 118 | 32 | $4.43 | $523 |
| 99211 Office E&M - Established | Office | 118 | 34 | $15.16 | $1,789 |
| 84100 Clinical Chemistry | Office | 117 | 25 | $4.65 | $544 |
| 96415 Chemotherapy Administration | Office | 117 | 16 | $18.84 | $2,204 |
By year: 2022 $1.0M for 70,410 services; 2023 $1.3M for 69,337 services; 2024 $1.2M for 43,925 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 1,119 | 224 | $7.58 | $8,481 |
| 36415 Venipuncture Blood Collection | 913 | 218 | $8.60 | $7,850 |
| 80053 Clinical Chemistry | 831 | 203 | $10.34 | $8,593 |
| 82784 Immunoassay | 463 | 45 | $9.11 | $4,219 |
| 83615 Clinical Chemistry | 261 | 53 | $5.92 | $1,545 |
| 84550 Clinical Chemistry | 118 | 32 | $4.43 | $523 |
| 84100 Clinical Chemistry | 117 | 25 | $4.65 | $544 |
| 83735 Clinical Chemistry | 93 | 16 | $6.57 | $611 |
| 84165 Clinical Chemistry | 75 | 16 | $10.53 | $790 |
| 86334 Immunoassay | 70 | 17 | $21.89 | $1,532 |
Medicare prescription drug claims, 2024
In 2024, the drug Ian W Flinn prescribed most often to Medicare patients was Calquence (Acalabrutinib Maleate), with 134 prescriptions and refills. In total Ian W Flinn wrote 960 Medicare prescriptions that cost $7.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Calquence Acalabrutinib Maleate | 134 | 134 | 14 | $1.9M |
| Acyclovir Generic | 122 | 196 | 36 | $2,142 |
| Brukinsa Zanubrutinib | 116 | 116 | 13 | $1.6M |
| Venclexta Venetoclax | 94 | 94 | 15 | $973K |
| Imbruvica Ibrutinib | 56 | 56 | Under 11 | $918K |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 49 | 55 | Under 11 | $285 |
| Jaypirca Pirtobrutinib | 29 | 29 | Under 11 | $606K |
| Dexamethasone Generic | 28 | 30 | Under 11 | $550 |
| Pomalyst Pomalidomide | 26 | 26 | Under 11 | $547K |
| Famotidine Generic | 17 | 27 | Under 11 | $266 |
| Valacyclovir Valacyclovir Hcl | 16 | 20 | Under 11 | $477 |
| Revlimid Lenalidomide | 15 | 15 | Under 11 | $244K |
| Allopurinol Generic | 15 | 27 | Under 11 | $119 |
| Levofloxacin Generic | 14 | 16 | Under 11 | $177 |
| Eliquis Apixaban | 13 | 19 | Under 11 | $12K |
Brand drugs: 553 claims; generic drugs: 407 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Ian W Flinn $15K ($9,068 in general payments such as food, travel and fees and $5,507 for research) from 38 companies. The largest payer was F. Hoffmann-La Roche AG with $5,507.
| Company | Payments | Amount |
|---|---|---|
| F. Hoffmann-La Roche AG ROG.SW | 7 | $5,507 |
| Gilead Sciences, Inc. GILD | 1 | $3,050 |
| BeOne Medicines USA, Inc. ONC | 4 | $1,916 |
| Abbvie Inc. ABBV | 6 | $1,470 |
| Kite Pharma, Inc. GILD | 3 | $930 |
| Genentech USA, Inc. ROG.SW | 3 | $211 |
| Lilly USA, LLC LLY | 3 | $172 |
| AstraZeneca Pharmaceuticals LP AZN | 5 | $160 |
| Stemline Therapeutics Inc. | 2 | $143 |
| Novartis Pharmaceuticals Corporation NVS | 5 | $136 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.